Text Size

Role of Magnetic Resonance Imaging (MRI) Perfusion to Detect Disease in Prostate Carcinoma

This study has been completed.
Sponsor:
Collaborator:
Princess Margaret Hospital, Canada
Information provided by:
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT00230386
First received: September 28, 2005
Last updated: July 10, 2009
Last verified: September 2005
History of Changes

September 28, 2005
July 10, 2009
May 2003
Not Provided
To determine whether there may be a role for MRI perfusion in the detection of recurrent or persistent prostatic cancer after previous radiotherapy
To determine whether there may be a role for MRI perfusion in the detection of recurrent or persistent prostatic cancer after previous radiotherapy.
Complete list of historical versions of study NCT00230386 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Role of Magnetic Resonance Imaging (MRI) Perfusion to Detect Disease in Prostate Carcinoma
The Role of MRI Perfusion to Detect Locally Recurrent or Persistent Disease in Prostate Carcinoma Treated With Radiation Therapy - A Pilot Study

This is a pilot study of 50 patients to establish whether there is a potential role for MRI perfusion in the detection of locally recurrent or persistent prostate carcinoma after previous treatment with radiotherapy. All subjects will be patients who have had localised prostate cancer treated with radiotherapy and have already agreed to undergo a biopsy of the prostate to look at local control within the prostate as part of their management. The objective of the study is to establish whether there is a relationship between recurrent or persistent disease within the prostate and increased perfusion on MRI at these sites.
Not Provided
Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostatic Neoplasms
Device: MRI
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
Not Provided
Not Provided

Inclusion Criteria:

  • Previously have had radical radiotherapy for localised prostate cancer
  • Due to undergo routine post-treatment prostatic biopsies
  • Suitable for MRI scan
  • Adequate renal function
  • No previous reaction to gadolinium
  • Able to give informed consent
  • No recent prostate biopsy within 6 weeks of enrolment
  • Performance status (Eastern Cooperative Oncology Group [ECOG]) 0 or 1

Exclusion Criteria:

  • Not suitable for MRI scan
  • Previous reaction to gadolinium
  • Impaired renal function
  • Inability to give informed consent
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00230386
UHN REB 03-0272-CE
Not Provided
Not Provided
University Health Network, Toronto
Princess Margaret Hospital, Canada
Principal Investigator: Michael Milosevic, MD Princess Margaret Hospital, Canada
University Health Network, Toronto
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP